.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech expect to note on the Nasdaq under the symbol "BIOA," according to files filed along with the Securities and Swap Percentage. The firm has actually not publicly shared an anticipated monetary volume for the offering.The clinical-stage company touts lead candidate azelaprag, a by mouth provided little particle slated to get into stage 2 screening in combo with semaglutide-- offered through Novo Nordisk under trademark name Wegovy for weight loss-- in the initial one-half of following year. Semaglutide is likewise offered as Ozempic and also Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is designed to blend properly with GLP-1 drugs, enhancing fat loss while protecting muscle mass. The investigational drug was actually discovered to be well-tolerated among 265 people throughout eight stage 1 tests, depending on to BioAge.Previously, BioAge achieved the support of Lilly to manage a trial integrating azelaprag along with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro as well as Zepbound for weight management. The partners are currently performing a phase 2 trial of azelaprag and tirzepatide, with topline end results expected in the third quarter of 2025.The biotech is actually also considering a blood insulin sensitivity proof-of-concept trial assessing azelaprag as a monotherapy in the first one-half of following year to support potential evidence growth. In addition, the provider considers to ask the FDA for authorization in the second one-half of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic conditions as well as neuroinflammation.BioAge's anticipated transfer to the public market follows a small uptick in organized biotech IPOs from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the current IPO garden is actually a "combined photo," with top notch business still debuting on everyone markets, only in lowered varieties, according to PitchBook.